Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitrous oxide (N2O), commonly known as laughing gas, is an inhalational anesthetic being investigated as a rapid-acting treatment for treatment-resistant depression (TRD). In the SMILE (Sustained Mood Improvement with Laughing Gas Exposure) trial led by Women's College Hospital, it is administered at a 50% concentration for one hour in combination with intravenous saline. Nitrous oxide acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist, a mechanism shared with ketamine, which is thought to modulate glutamatergic neurotransmission to alleviate depressive symptoms. This specific combination and protocol are being evaluated for their ability to provide sustained mood improvement in patients who have failed multiple standard antidepressant therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nitrous oxide + saline.